Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.43 |
| ▸ | DAO | P14920 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18871230 | 0.84 | TDP1 (0.41) | TDP1DAO | |
| SCHEMBL18870685 | 0.80 | TDP1 (0.40) | TDP1SMN1; SMN2CYP2C19ALDH1A1CYP1A2 | |
| SCHEMBL18870686 | 0.79 | TDP1 (0.52) | TDP1DAOCRBN | |
| SCHEMBL17040216 | 0.72 | TDP1 (0.52) | TDP1DAOSMN1; SMN2GLACRBN | |
| SCHEMBL17041835 | 0.70 | TDP1 (0.53) | TDP1DAOSMN1; SMN2GLAMAPT | |
| SCHEMBL20052235 | 0.68 | TDP1 (0.47) | TDP1DAOSMN1; SMN2CRBN | |
| SCHEMBL19403626 | 0.67 | MEN1 (0.36) | DAOMEN1KMT2A | |
| SCHEMBL21350419 | 0.65 | GPR84 (0.32) | — | |
| SCHEMBL8303043 | 0.64 | TDP1 (0.45) | TDP1DAOMAPTCRBNALDH1A1 | |
| SCHEMBL19545774 | 0.62 | KDM4E (0.50) | DAOSMN1; SMN2MAPTALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190255194-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | MODERNATX INC (US) | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190255194-A1 | ALTERNATIVE NUCLEIC ACID MOLECULES AND USES THEREOF | NSUN2, RNGTT, NSUN3 | TDP1 176/4885DAO 3699/4885SMN1; SMN2 744/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.